Shaily Engineering Plastics Limited has informed the Exchange about Investor Presentation
SEPL/SE/Feb/24-25 10th February 2025
The General Manager, Corporate Relations/Listing Department BSE Limited Floor 25, P.J. Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 501423
The Manager, Listing Department National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra – Kurla Complex, Bandra (E), Mumbai – 400 051 Scrip Code: SHAILY
Sub: Q3FY25 - Result Presentation
Ref:
Regulation 30 of the SEBI Listing Regulations, 2015
Dear Sir,
In continuation to our letter dated 4th February 2025, regarding intimation of Earnings Call of the Company scheduled on Monday, 10th February 2025, to discuss the Operational & Financial performance of the Company for the quarter and nine months ended on 31st December 2024, kindly find enclosed herewith Q3FY25 Result Presentation of the Company.
A copy of the same is also available on our website www.shaily.com.
Kindly take the same on record.
Thanking You.
Yours truly, For Shaily Engineering Plastics Limited
Harish Punwani Company Secretary & Compliance Officer M. No. A50950
Encl: a/a
Shaily Engineering Plastics Ltd
Investors Presentation February 2025
Safe Harbor
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Shaily Engineering Plastics Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.
2
Key Performance Highlights
Business Updates for Q3 FY25
Healthcare Successful participant in Pharma Pack 2025, Paris
Participation in Pharma Pack exhibition in Paris to showcase our innovations in medical device space
Consumer New Business awarded
Awarded business from 2 global retail chains and supplies to start from Q1/Q2 FY26
Healthcare Signed 6 contracts for Pen Injectors
Signed 6 contracts with different customers for Pen Injectors for GLP 1 / Other therapies
Consumer Successful participant in Cosmoprof, Mumbai
Participation in Cosmoprof exhibition in Mumbai to showcase our speciality packaging expertise
4
Key Financial Highlights – Q3 & 9M FY25 (Consolidated*)
Revenues
Gross Profit Margin
EBITDA
+25%
197.6
158.4
+20%
569.0
473.3
+360 bps
+440 bps
43.9%
47.5%
41.0%
45.4%
+40%
46.3
+42%
123.8
33.0
87.2
Q3FY24 Q3FY25
9MFY24
9MFY25
Q3FY24 Q3FY25
9MFY24
9MFY25
Q3FY24 Q3FY25
9MFY24
9MFY25
EBITDA Margins
Profit After Tax
Cash PAT#
+260 bps
+330 bps
20.8%
23.4%
21.7%
18.4%
+73%
25.2
+70%
64.5
14.5
38.0
+50%
35.9
+50%
95.6
23.9
63.6
Q3FY24 Q3FY25
9MFY24
9MFY25
Q3FY24 Q3FY25
9MFY24
9MFY25
Q3FY24 Q3FY25
9MFY24
9MFY25
(Rs. Cr.)
#Cash PAT includes PAT & Depreciation
* Includes the UK Subsidiary Business
5
Key Financial Highlights – Q3 & 9M FY25 (Standalone)
Revenues
Gross Profit Margin
EBITDA
+29%
186.3
144.7
+18%
534.8
453.2
+580 bps
+350 bps
38.6%
44.4%
38.4%
41.9%
+73%
38.5
22.2
+38%
98.6
71.5
Q3FY24 Q3FY25
9MFY24
9MFY25
Q3FY24 Q3FY25
9MFY24
9MFY25
Q3FY24 Q3FY25
9MFY24
9MFY25
EBITDA Margins
Profit After Tax
Cash PAT#
+520 bps
+260 bps
20.6%
18.4%
15.8%
15.4%
+192%
18.1
+67%
41.4
+83%
28.0
6.2
24.7
15.3
+41%
70.4
50.0
Q3FY24 Q3FY25
9MFY24
9MFY25
Q3FY24 Q3FY25
9MFY24
9MFY25
Q3FY24 Q3FY25
9MFY24
9MFY25
(Rs. Cr.)
#Cash PAT includes PAT & Depreciation
6
Operational Trends
+697 bps
+248 bps
44.6%
40.2%
42.7%
37.6%
Revenue Analysis – Domestic vs. Exports
Q3 FY24
vs
Q3 FY25
26.6%
20.6%
n o i t a z i l i t U e n h c a M
i
)
%
(
l
s t n a P s s o r c A
Q3FY24
Q3FY25
9MFY24
9MFY25
73.4%
79.5%
s r e m y l o P f o e m u o V
l
) T M
( d e s s e c o r P
+21%
6,308
5,223
+10%
16,718
18,396
Q3FY24
Q3FY25
9MFY24
9MFY25
9MFY24
vs
9MFY25
25.8%
21.4%
74.2%
78.6%
7
Profit & Loss Statement
Particulars (Rs. Cr.)
Q3 FY25
Q3 FY24
YoY %
9M FY25
9M FY24
YoY %
Q3 FY25
Q3 FY24
YoY %
9M FY25
9M FY24
YoY %
Consolidated
Standalone
158.4
25%
Revenue
Raw Material
Employee Expenses
Other Expenses*
Other Income
EBITDA
197.6
103.7
19.6
28.4
0.4
46.3
88.8
14.7
23.0
1.1
33.0
EBITDA Margin
23.4%
20.8%
Depreciation
Finance Cost
PBT
PBT Margin
Tax
PAT
PAT Margin
Cash PAT^
Cash PAT Margin
10.7
4.1
31.5
15.9%
6.3
25.2
12.8%
35.9
18.1%
9.4
5.0
18.6
11.7%
4.0
14.5
9.2%
23.9
15.1%
40%
70%
73%
50%
569.0
310.6
57.2
79.6
2.2
123.8
21.7%
31.1
13.0
79.7
473.3
279.3
41.5
70.3
4.9
87.2
18.4%
25.7
13.2
48.3
14.0%
10.2%
15.1
64.5
11.3%
95.6
16.8%
10.3
38.0
8.0%
63.6
13.4%
20%
42%
65%
70%
50%
186.3
103.7
17.6
27.0
0.4
38.5
144.7
29%
88.8
14.5
20.2
1.1
22.2
73%
534.8
310.6
53.1
75.5
2.9
98.6
453.2
279.3
40.9
66.5
4.9
71.5
20.6%
15.4%
18.4%
15.8%
9.9
4.1
24.4
13.1%
6.3
18.1
9.7%
28.0
9.0
5.0
8.2
5.7%
2.0
6.2
4.3%
15.3
29.1
13.0
56.5
10.6%
15.1
41.4
7.7%
70.4
25.2
13.2
33.0
7.3%
8.3
24.7
5.5%
50.0
198%
192%
83%
15.0%
10.6%
13.2%
11.0%
18%
38%
71%
67%
41%
* Other Expenses include Power & Fuel costs
^ Cash PAT = PAT + Depreciation
8
Balance Sheet
Particulars (Rs. Crs.) Non-Current assets Property, Plant and Equipments Capital Work in Process Intangible assets Investments Intangible assets under development Financial Assets Loans Other Non-Current Assets Income tax assets Total Non-Current Assets Current Assets Inventories Financial Assets Trade Receivables Cash and Cash Equivalents Loans Other Current Assets Current tax assets (Net) Total Current Assets Total Assets
Sep-24
Mar-24
429.6 26.7 36.0 0.0 8.6
0.5 20.1 1.2 522.6
435.4 15.3 38.0 0.0 5.1
0.5 18.3 2.7 515.3
101.7
83.6
136.7 15.0 0.5 38.7 0.0 292.6 815.2
117.4 26.4 6.4 33.5 0.0 267.2 782.5
Particulars (Rs. Crs.) Equity Equity Share Capital Other Equity
Total Equity Non-Current Liabilities Financial Liabilities Long-term borrowings Deferred tax liabilities (net) Other long-term liabilities Long-term provisions
Total Non-Current Liabilities Current Liabilities Short-term borrowings Trade payables Other financial liabilities Other current liabilities Short-term provisions Current tax liabilities (net) Total Current Liabilities
Total Equity and Liabilities
Sep-24
Mar-24
9.2 485.6
494.8
53.2 23.0 0.4 2.6
79.2
122.2 91.7 9.8 12.2 4.7 0.7 241.2
815.2
9.2 450.0
459.2
69.8 20.8 1.2 2.2
94.1
138.5 68.7 10.3 10.4 1.3 0.0 229.2
782.5
On Consolidated basis
9
Balance Sheet
Particulars Non-Current assets Property, Plant and Equipments Capital Work in Process Intangible assets Investments Intangible assets under development Financial Assets Loans Other Non-Current Assets Income tax assets Total Non-Current Assets Current Assets Inventories Financial Assets Trade Receivables Cash and Cash Equivalents Loans Other Current Assets Current tax assets (Net) Total Current Assets Total Assets
Sep-24
Mar-24
428.4 26.7 16.8 11.3 3.5
0.5 20.1 0.0 507.2
434.9 15.3 17.8 20.6 2.1
0.5 18.3 2.3 511.8
101.7
83.6
113.8 5.8 0.5 32.3 0.0 254.1 761.3
111.7 8.6 6.4 29.9 0.0 240.3 752.1
Particulars Equity Equity Share Capital Other Equity
Total Equity Non-Current Liabilities Financial Liabilities Long-term borrowings Deferred tax liabilities (net) Other long-term liabilities Long-term provisions
Total Non-Current Liabilities Current Liabilities Short-term borrowings Trade payables Other financial liabilities Other current liabilities Short-term provisions Current tax liabilities (net) Total Current Liabilities
Total Equity and Liabilities
Sep-24
Mar-24
9.2 439.8
449.0
53.2 21.9 0.4 2.6
78.1
122.2 90.5 9.8 6.4 4.7 0.7 234.2
761.3
9.2 422.3
431.5
69.8 20.4 1.2 2.2
93.6
138.5 67.2 10.3 9.7 1.3 0.0 227.0
752.1
On Standalone basis
10
Cash Flow Statement
Particulars (Rs. Cr.)
Profit Before Tax
Adjustments
Operating profit before working capital changes
Changes in working capital
Cash generated from operations
Direct taxes paid (net of refund)
Net Cash from Operating Activities
Net Cash from Investing Activities
Net Cash from Financing Activities
Net Change in cash and cash equivalents
Add: Cash & Cash equivalents at the beginning of the period
Closing Cash Balance
On Consolidated basis
Consolidated
Standalone
H1 FY25
H1 FY24
H1 FY25
H1 FY24
48.2
28.4
76.6
-6.6
69.9
-3.6
66.3
-32.2
-45.9
-11.8
22.2
10.4
29.7
23.3
53.0
-12.0
41.0
-3.9
37.1
-51.8
15.2
0.5
19.1
19.6
32.1
23.8
55.9
9.5
65.4
-3.6
61.8
-19.2
-45.9
-3.3
4.4
1.2
24.8
23.2
48.0
-8.5
39.4
-3.9
35.6
-54.6
15.2
-3.8
17.7
13.9
11
Efficient Use of Capital
Revenue Breakup (Rs. Crs.)
Q3 FY24
Q3 FY25
17.1%
8.6%
158
198
22.1%
6.3%
74.3%
71.5%
RoCE
+510 bps
RoE
+470 bps
22.8%
18.0%
17.7%
13.3%
Consumer
Healthcare
Industrial
Mar-24
Dec-24
Mar-24
Dec-24
Revenue Breakup (Rs. Crs.)
Fixed Asset Turnover
Total Debt / Equity
9M FY24
9M FY25
14.6%
8.4%
19.1%
8.4%
1.48
473
569
1.68
0.5 0.5
0.4 0.4
77.0%
72.5%
Consumer
Healthcare
Industrial
On Consolidated basis
Mar-24
Dec-24
Mar-24 Mar-24
Dec-24 Dec-24
12
About the Company
Enriching Lives Through Plastics
Shaily Engineering Plastics Limited is India’s largest exporter of plastics components. Established in 1987, the Company provides end-to-end solutions in plastic products and services, whilst delivering superior quality and value to all stakeholders. The Company employs over 2,000+ employees and have over 200+ injection molding machines, with precise, high speed automated and robotic production lines.
Founded in 1987
Revenue* Rs. 644 Crores FY 24
7 Facilities in Gujarat 6 for Plastic 1 for Steel Furniture
Long-standing global relationships with marquee clients
200+ Injection moulding machines
Over 2,000 employees across 7 plants
De-risked Business Model
* On Consolidated Basis
13
Business Segments
Consumer
Industrial
Healthcare
✓ Home Furnishings
✓ FMCG Packaging
✓ LED Lights
✓ Toys
✓ Carbon Steel Furniture
✓ Automotive Components
✓ Appliances
✓ High Performance Engineering Components
✓ Platform Devices
✓ Drug Delivery Devices
✓ Pharma Packaging
14
State-of-the-Art Manufacturing Facilities
7 Facilities with over 200 molding machines ranging from 35 tons to 1,000 tons
Rania
Halol
GUJARAT
Rania
❖ Export Oriented Unit ❖ Pharma (Dedicated ISO Class 8 clean
room manufacturing facility)
❖ Others
Halol (Existing)
❖ Automotive & Engineering
Halol (New)
❖ Carbon Steel ❖ Plastic
Disclaimer: Maps not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.
15
Board of Directors
Executive Chairman
Mr. Mahendra Sanghvi
Whole Time Director
Ms. Tilottama Sanghvi
Managing Director
Mr. Amit Sanghvi
Executive Director
Mr. Laxman Sanghvi
Independent Director
Dr. Shailesh Ayyangar
Independent Director
Mr. Ranjit Singh
Independent Director
Mr. Samaresh Parida
Independent Director
Mrs. Sangeeta Singh
16
Strong Credit Rating*
LONG TERM BANK FACILITIES
Rs. 238.45 Crs.; reduced from Rs. 283 Crs.
CARE A; Outlook: Stable
Rating Action: Reaffirmed
SHORT TERM BANK FACILITIES
Rs. 35 Crs.
CARE A1
Rating Action: Reaffirmed
Long and established track record in the plastic injection molding business along with experienced Promoters
Growth in Total operating income on the back of increased volumes & higher exports
Sustainable healthy operating margin along with strengthening leverage and debt coverage indicators
New business confirmations from existing clients along with addition of marquee clients across diversified industries
Sustainable healthy operating margin along with strengthening leverage and debt coverage indicators
*Updated as on 30th September 2024
17
Historical Profit & Loss Statement
Particulars (Rs. Cr.)
Revenue
Raw Material
Employee Expenses
Other Expenses*
Other Income
EBITDA
EBITDA Margin
Depreciation
Finance Cost
PBT
PBT Margin
Tax
PAT
PAT Margin
Cash PAT^
Cash PAT Margin
Consolidated
Standalone
FY24
643.9
370.1
57.3
99.5
6.5
123.4
19.2%
35.7
17.9
69.8
10.8%
12.6
57.3
8.9%
93.0
14.4%
FY23
607.1
386.5
47.9
80.8
4.5
96.4
15.9%
33.3
17.9
45.2
7.4%
10.1
35.1
5.8%
68.5
11.3%
FY24
616.0
370.1
55.9
95.2
6.5
101.3
16.4%
34.7
17.9
48.7
7.9%
12.6
36.1
5.9%
70.8
11.5%
FY23
599.7
386.5
47.2
79.4
4.5
91.1
15.2%
33.2
17.9
40.1
6.7%
10.1
30.0
5.0%
63.2
10.5%
* Other Expenses include Power & Fuel costs
^ Cash PAT = PAT + Depreciation
18
Historical Balance Sheet
Particulars
Non-Current assets Property, Plant and Equipments Capital Work in Process Intangible assets Investments Intangible assets under development Financial Assets Loans Other Non-Current Assets Income tax assets
Total Non-Current Assets
Current Assets Inventories Financial Assets Trade Receivables Cash and Cash Equivalents Loans
Other Current Assets
Current tax assets (Net)
Total Current Assets
Total Assets
On Consolidated basis
Mar-24
Mar-23
Particulars
Mar-24
Mar-23
435.4 15.3 38.0 0.0 5.1
0.5 18.3 2.7
515.3
83.6
117.4 26.4 6.4
33.5
0.0
267.2
782.5
347.9 49.0 19.0 0.0 19.3
0.5 17.2 2.1
455.0
73.0
91.9 23.0 5.7
44.1
0.0
237.7
692.7
Equity
Equity Share Capital
Other Equity
Total Equity
Non-Current Liabilities
Financial Liabilities
Long-term borrowings
Deferred tax liabilities (net)
Other long-term liabilities
Long-term provisions
Total Non-Current Liabilities
Current Liabilities
Short-term borrowings
Trade payables
Other financial liabilities
Other current liabilities
Short-term provisions
Current tax liabilities (net)
Total Current Liabilities
Total Equity and Liabilities
9.2
450.0
459.2
69.8
20.8
1.2
2.2
94.1
9.2
392.2
401.4
62.5
17.0
1.2
2.3
83.1
138.5
124.3
68.7
10.3
10.4
1.3
0.0
229.2
782.5
53.4
9.3
20.0
1.2
0.0
208.2
692.7
19
Historical Balance Sheet
Particulars
Non-Current assets Property, Plant and Equipments Capital Work in Process Intangible assets Investments Intangible assets under development Financial Assets Loans Other Non-Current Assets Income tax assets
Total Non-Current Assets
Current Assets Inventories Financial Assets Trade Receivables Cash and Cash Equivalents Loans
Other Current Assets
Current tax assets (Net)
Total Current Assets
Total Assets
On Standalone basis
Mar-24
Mar-23
Particulars
Mar-24
Mar-23
434.9 15.3 17.8 20.6 2.1
0.5 18.3 2.3
511.8
83.6
111.7 8.6 6.4
29.9
0.0
240.3
752.1
348.6 49.0 13.8 15.4 5.7
0.5 17.2 2.1
452.3
73.0
88.8 17.7 13.7
39.2
0.0
232.4
684.6
Equity
Equity Share Capital
Other Equity
Total Equity
Non-Current Liabilities
Financial Liabilities
Long-term borrowings
Deferred tax liabilities (net)
Other long-term liabilities
Long-term provisions
Total Non-Current Liabilities
Current Liabilities
Short-term borrowings
Trade payables
Other financial liabilities
Other current liabilities
Short-term provisions
Current tax liabilities (net)
Total Current Liabilities
Total Equity and Liabilities
9.2
422.3
431.5
69.8
20.4
1.2
2.2
93.6
138.5
67.2
10.3
9.7
1.3
0.0
227.0
752.1
9.2
386.5
395.6
62.5
16.9
1.2
2.3
82.9
123.2
51.7
10.4
19.5
1.2
0.0
206.1
684.6
20
Cash Flow Statement
Consolidated
Standalone
Particulars (Rs. Cr.)
Profit Before Tax
Adjustments
Operating profit before working capital changes
Changes in working capital
Cash generated from operations
Direct taxes paid (net of refund)
Net Cash from Operating Activities
Net Cash from Investing Activities
Net Cash from Financing Activities
Net Change in cash and cash equivalents
Add: Cash & Cash equivalents at the beginning of the period
Closing Cash Balance
FY24
69.8
58.2
128.0
-27.0
101.0
-8.8
92.3
-99.0
9.8
3.1
19.1
22.2
FY23
45.2
51.4
96.6
-0.6
96.0
-6.0
90.0
-100.9
-5.1
-16.0
35.1
19.1
FY24
48.7
56.2
104.8
-21.6
83.3
-8.8
74.5
-92.4
4.6
-13.3
17.7
4.4
FY23
40.1
50.4
90.5
0.2
90.7
-6.0
84.7
-93.3
-5.1
-13.7
31.4
17.7
21
Contact
Company :
Investor Relations Advisors :
Shaily Engineering Plastics Ltd. CIN – L51900GJ1980PLC065554
Mr. Sanjay Shah, Chief Strategy Officer sanjay@shaily.com
www.shaily.com
Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285
Mr. Shogun Jain / Mr. Deven Dhruva shogun.jain@sgapl.net / deven.dhruva@sgapl.net +91 77383 77756 / +91 98333 73300 www.sgapl.net
22